Search

Your search keyword '"Koura, Divya"' showing total 41 results
Start Over Author "Koura, Divya" Publication Year Range Last 50 years
41 results on '"Koura, Divya"'

1. Liver disease and transplantation in telomere biology disorders: An international multicenter cohort.

Author

Wang, YunZu, Kaj-Carbaidwala, Batul, Lane, Adam, Agarwal, Suneet, Beier, Fabian, Bertuch, Alison, Borovsky, Kristin, Brennan, Steven, Calado, Rodrigo, Catto, Luiz, Dufour, Carlo, Ebens, Christen, Fioredda, Francesca, Giri, Neelam, Gloude, Nicholas, Goldman, Frederick, Hertel, Paula, Himes, Ryan, Keel, Sioban, Koura, Divya, Kratz, Christian, Kulkarni, Sakil, Liou, Iris, Nakano, Taizo, Nastasio, Silvia, Niewisch, Marena, Penrice, Daniel, Sasa, Ghadir, Savage, Sharon, Simonetto, Douglas, Ziegler, David, Miethke, Alexander, and Myers, Kasiani

Subjects
Humans, Liver Transplantation, Female, Male, Retrospective Studies, Adult, Middle Aged, Telomere, Adolescent, Liver Diseases, Young Adult, Child, Treatment Outcome, Child, Preschool
Abstract

BACKGROUND: Patients with telomere biology disorders (TBD) develop hepatic disease, including hepatitis, cirrhosis, and hepatopulmonary syndrome. No specific treatment exists for TBD-related liver disease, and the role of liver transplantation (LT) remains controversial. Our study objectives were to describe the clinical characteristics, management, and outcomes in patients with TBD-related liver disease, and their LT outcomes. METHODS: Data from 83 patients with TBD-associated liver disease were obtained from 17 participating centers in the Clinical Care Consortium of Telomere-Associated Ailments and by self-report for our retrospective, multicenter, international cohort study. RESULTS: Group A (Advanced) included 40 patients with advanced liver disease. Of these, 20 underwent LT (Group AT). Group M (Mild) included 43 patients not warranting LT evaluation, none of whom were felt to be medically unfit for liver transplantation. Supplemental oxygen requirement, pulmonary arteriovenous malformation, hepatopulmonary syndrome, and higher bilirubin and international normalized ratio values were associated with Group A. Other demographics, clinical manifestations, and laboratory findings were similar between groups. Six group A patients were declined for LT; 3 died on the waitlist. Median follow-up post-LT was 2.9 years (range 0.6-13.2 y). One-year survival post-LT was 73%. Median survival post-LT has not been reached. Group AT patients had improved survival by age compared to all nontransplant patients (log-rank test p = 0.02). Of 14 patients with pretransplant hypoxemia, 8 (57%) had improved oxygenation after transplant. CONCLUSIONS: LT recipients with TBD do not exhibit excessive posttransplant mortality, and LT improved respiratory status in 57%. A TBD diagnosis should not exclude LT consideration.

Published
2024

2. A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis.

Author

Dykes, Kaitlyn, Tzachanis, Dimitrios, and Koura, Divya

Subjects
T cells, bone marrow, cancer, graft versus host disease, oncology, Humans, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Calcineurin Inhibitors, Abatacept, Male, Middle Aged, Immunosuppressive Agents, Adult, Female
Abstract

Post-allogeneic hematopoietic cell transplant (HCT) immunosuppression regimens are given as graft-versus-host disease (GVHD) prophylaxis. Most GVHD prophylaxis regimens are based on calcineurin inhibitors (CNIs). Unfortunately, CNIs are associated with significant associated morbidity, frequently cannot be tolerated, and often need to be discontinued. There is no consensus as to which alternative immunosuppression should be used in cases where CNIs have to be permanently discontinued. Cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA4-Ig) blocking agents are well tolerated and have been used extensively in patients with autoimmune disease and as post-transplant immunosuppression. There are two CTLA4-Ig agents: belatacept and abatacept. Belatacept is routinely used in adult kidney transplantation to prevent rejection and abatacept has been approved by the Food and Drug Administration (FDA) for GVHD prophylaxis in patients undergoing a matched or one allele-mismatched unrelated allogenic HCT. Herein, we describe a case in which abatacept was given off-label to replace tacrolimus GVHD prophylaxis in a patient with neurotoxicity undergoing haploidentical HCT. This case suggests that CTLA4-Ig blockade may be a good alternative to a CNI in cases where the CNI needs to be discontinued and warrants further investigation.

Published
2024

3. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Author

Roloff, Gregory W., Aldoss, Ibrahim, Kopmar, Noam E., Lin, Chenyu, Dekker, Simone E., Gupta, Vishal K., OʼConnor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Ahmed, Naveed, Zhang, Amy, Miller, Katharine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan C., Mercadal, Santiago, Schwartz, Marc, Tracy, Sean I., Dholaria, Bhagirathbhai, Mukherjee, Akash, Battiwalla, Minoo, Logan, Aaron C., Ladha, Abdullah, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew P., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua P., Solh, Melhem M., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Pullarkat, Vinod, Stock, Wendy, Cassaday, Ryan D., Shah, Bijal D., Faramand, Rawan, Muffly, Lori, Oliai, Caspian, Yaghmour, George, Sutherland, Katherine, Zambrano, Hector, Bradshaw, Danielle, Kubiak, Michal, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Advani, Anjali S., Stefan, Maryann, OʼDwyer, Kristen M., Lee, Catherine J., Blunk, Betsy, and Bishop, Michael R.

Published
2024
Full Text
View/download PDF

4. NCCN Guidelines® Insights: Survivorship, Version 1.2023.

Author

Sanft, Tara, Day, Andrew, Ansbaugh, Shannon, Armenian, Saro, Baker, K Scott, Ballinger, Tara, Demark-Wahnefried, Wendy, Dickinson, Kristin, Fairman, Nathan Paul, Felciano, Josephine, Flores, Tessa Faye, Friedman, Debra L, Gabel, Nicolette M, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Koura, Divya, Lee, Kimberly, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle C F, Moryl, Natalie, Neuman, Heather, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Peterson, Lindsay, Pirl, William, Porpiglia, Andrea, Rodriguez, M Alma, Schapira, Lidia, Schwartz, Anna L, Smith, Sophia, Tevaarwerk, Amye, Yang, Eric, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Subjects
Adult, Humans, Survivorship, Neoplasms: diagnosis, therapy, psychology, Survivors, Cancer Survivors: psychology, Immunization
Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals address the complex and varied needs of cancer survivors. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for psychosocial and physical problems resulting from adult-onset cancer and its treatment; recommendations to help promote healthy behaviors and immunizations in survivors; and a framework for care coordination. These NCCN Guidelines Insights summarize recent guideline updates and panel discussions pertaining to sleep disorders, fatigue, and cognitive function in cancer survivors.

Published
2023

5. NCCN Guidelines® Insights: Survivorship, Version 1.2022.

Author

Sanft, Tara, Day, Andrew, Peterson, Lindsay, Rodriguez, M Alma, Ansbaugh, Shannon, Armenian, Saro, Baker, K Scott, Ballinger, Tarah, Broderick, Gregory, Demark-Wahnefried, Wendy, Dickinson, Kristin, Fairman, Nathan Paul, Friedman, Debra L, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle C F, Moryl, Natalie, Neuman, Heather, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Pirl, William, Porpiglia, Andrea, Ruddy, Kathryn J, Schapira, Lidia, Shockney, Lillie, Smith, Sophia, Syrjala, Karen L, Tevaarwerk, Amye, Yang, Eric H, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals who work with survivors to ensure that the survivors' complex and varied needs are addressed. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for the consequences of adult-onset cancer and its treatment; recommendations to help promote physical activity, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes updates to the NCCN Guidelines pertaining to preventive health for cancer survivors, including recommendations about alcohol consumption and vaccinations.

Published
2022

6. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Author

Aldoss, Ibrahim, Roloff, Gregory W., Faramand, Rawan, Kopmar, Noam E., Lin, Chenyu, Advani, Anjali S., Dekker, Simone E., Gupta, Vishal K., O'Connor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Zhang, Amy, Miller, Katharine, Sutherland, Katherine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew, O'Dwyer, Kristen M., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Bishop, Michael R., Stock, Wendy, Cassaday, Ryan D., Pullarkat, Vinod, Shah, Bijal D., and Muffly, Lori S.

Published
2024
Full Text
View/download PDF

7. Survivorship, Version 1.2021.

Author

Tevaarwerk, Amye, Denlinger, Crystal S, Sanft, Tara, Ansbaugh, Shannon M, Armenian, Saro, Baker, K Scott, Broderick, Gregory, Day, Andrew, Demark-Wahnefried, Wendy, Dickinson, Kristin, Friedman, Debra L, Ganz, Patricia, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle CF, Moryl, Natalie, Moslehi, Javid J, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Peterson, Lindsay, Pirl, William, Rodriguez, M Alma, Ruddy, Kathryn J, Schapira, Lidia, Shockney, Lillie, Smith, Sophia, Syrjala, Karen L, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Subjects
Health Services and Systems, Nursing, Health Sciences, Cancer, Rehabilitation, Prevention, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Adult, Cancer Survivors, Humans, Mass Screening, Neoplasms, Survivors, Survivorship, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals working with cancer survivors to ensure that each survivor's complex and varied needs are addressed. The Guidelines provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment; recommendations to help promote healthful lifestyle behaviors, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes the recommendations regarding employment and return to work for cancer survivors that were added in the 2021 version of the NCCN Guidelines.

Published
2021

8. NCCN Guidelines Insights: Survivorship, Version 2.2020.

Author

Denlinger, Crystal, Sanft, Tara, Moslehi, Javid, Overholser, Linda, Armenian, Saro, Baker, K, Broderick, Gregory, Demark-Wahnefried, Wendy, Friedman, Debra, Goldman, Mindy, Henry, Norah, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison, Melisko, Michelle, Mooney, Kathi, Moore, Halle, Moryl, Natalie, OConnor, Tracey, Paskett, Electra, Patel, Chirayu, Peterson, Lindsay, Pirl, William, Rodriguez, M, Ruddy, Kathryn, Shockney, Lillie, Smith, Sophia, Syrjala, Karen, Tevaarwerk, Amye, Zee, Phyllis, McMillian, Nicole, and Freedman-Cass, Deborah

Subjects
Adult, Body Weight Maintenance, Exercise, Humans, Immunization, Mass Screening, Neoplasms, Practice Guidelines as Topic, Survivors, Survivorship
Abstract

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment, with the goal of helping healthcare professionals who work with survivors, including those in primary care. The guidelines also provide recommendations to help clinicians promote physical activity, weight management, and proper immunizations in survivors and facilitate care coordination to ensure that all of the survivors needs are addressed. These NCCN Guidelines Insights summarize additions and changes made to the guidelines in 2020 regarding cardiovascular disease risk assessment and screening for subsequent primary malignancies.

Published
2020

9. NCCN Guidelines Insights: Survivorship, Version 2.2019.

Author

Sanft, Tara, Denlinger, Crystal, Armenian, Saro, Baker, K, Broderick, Gregory, Demark-Wahnefried, Wendy, Friedman, Debra, Goldman, Mindy, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, Lally, Robin, Langbaum, Terry, McDonough, Allison, Melisko, Michelle, Mooney, Kathi, Moore, Halle, Moslehi, Javid, OConnor, Tracey, Overholser, Linda, Paskett, Electra, Peterson, Lindsay, Pirl, William, Rodriguez, M, Ruddy, Kathryn, Smith, Sophia, Syrjala, Karen, Tevaarwerk, Amye, Urba, Susan, Zee, Phyllis, McMillian, Nicole, and Freedman-Cass, Deborah

Subjects
Body Weight Maintenance, Exercise, Guidelines as Topic, Humans, Neoplasms, Survivorship
Abstract

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of cancer and cancer treatment to aid healthcare professionals who work with survivors of adult-onset cancer. Guidance is also provided to help promote physical activity, weight management, and proper immunizations in survivors and to facilitate care coordination to ensure that all needs are addressed. These NCCN Insights summarize some of the topics discussed by the NCCN Survivorship Panel during the 2019 update of the guidelines, including the survivorship population addressed, ways to improve care coordination, and pain management.

Published
2019

10. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Author

Denlinger, Crystal, Sanft, Tara, Baker, K, Broderick, Gregory, Demark-Wahnefried, Wendy, Friedman, Debra, Goldman, Mindy, Hudson, Melissa, Khakpour, Nazanin, King, Allison, Koura, Divya, Lally, Robin, Langbaum, Terry, McDonough, Allison, Melisko, Michelle, Montoya, Jose, Mooney, Kathi, Moslehi, Javid, OConnor, Tracey, Overholser, Linda, Paskett, Electra, Peppercorn, Jeffrey, Pirl, William, Rodriguez, M, Ruddy, Kathryn, Silverman, Paula, Smith, Sophia, Syrjala, Karen, Tevaarwerk, Amye, Urba, Susan, Wakabayashi, Mark, Zee, Phyllis, McMillian, Nicole, and Freedman-Cass, Deborah

Subjects
Anthracyclines, Antibiotics, Antineoplastic, Antineoplastic Agents, Immunological, Bacterial Infections, Cancer Survivors, Cardiotoxicity, Humans, Immunocompromised Host, Lymphedema, Mass Screening, Medical Oncology, Neoplasms, Risk Assessment, Societies, Medical, Survivorship, United States, Vaccination, Virus Diseases
Abstract

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. This portion of the guidelines describes recommendations regarding the management of anthracycline-induced cardiotoxicity and lymphedema. In addition, recommendations regarding immunizations and the prevention of infections in cancer survivors are included.

Published
2018

11. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Author

Denlinger, Crystal, Sanft, Tara, Baker, K, Baxi, Shrujal, Broderick, Gregory, Demark-Wahnefried, Wendy, Friedman, Debra, Goldman, Mindy, Hudson, Melissa, Khakpour, Nazanin, King, Allison, Koura, Divya, Kvale, Elizabeth, Lally, Robin, Langbaum, Terry, Melisko, Michelle, Montoya, Jose, Mooney, Kathi, Moslehi, Javid, OConnor, Tracey, Overholser, Linda, Paskett, Electra, Peppercorn, Jeffrey, Rodriguez, M, Ruddy, Kathryn, Silverman, Paula, Smith, Sophia, Syrjala, Karen, Tevaarwerk, Amye, Urba, Susan, Wakabayashi, Mark, Zee, Phyllis, Freedman-Cass, Deborah, and McMillian, Nicole

Subjects
Female, Humans, Middle Aged, Medical Oncology, Menopause, Quality of Life, Survivorship
Abstract

Many cancer survivors experience menopausal symptoms, including female survivors taking aromatase inhibitors or with a history of oophorectomy or chemotherapy, and male survivors who received or are receiving androgen-ablative therapies. Sexual dysfunction is also common in cancer survivors. Sexual dysfunction and menopause-related symptoms can increase distress and have a significant negative impact on quality of life. This portion of the NCCN Guidelines for Survivorship provide recommendations for screening, evaluation, and treatment of sexual dysfunction and menopausal symptoms to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period.

Published
2017

13. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, primary, Tsai, Dr. Stephanie B., additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Kopmar, Noam E., additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Gupta, Vishal, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dholaria, Dr. Bhagirathbhai, additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Logan, Aaron C., additional, Tracy, Sean, additional, Kubiak, Michal, additional, Solh, Melhem M, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Mukherjee, Akash, additional, Battiwalla, Minoo, additional, Shaughnessy, Paul J., additional, Majhail, Navneet S., additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Ladha, Dr. Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Lee, Catherine J, additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Shah, Bijal D., additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

14. Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Author

Shah, Nirali N., primary, Azzi, Jacques, additional, Cooper, Brenda, additional, Deol, Abhinav, additional, DiPersio, John F., additional, Koura, Divya, additional, Magenau, John, additional, McClune, Brian, additional, Muffly, Lori S, additional, Mushtaq, Muhammad Umair, additional, Narayan, Rupa, additional, Suh, Hyung C., additional, Nath, Sritama, additional, Whangbo, Jennifer, additional, and Koehne, Guenther, additional

Published
2024
Full Text
View/download PDF

15. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

Author

DiPersio, John F., primary, Cooper, Brenda, additional, Suh, Hyung C., additional, Koura, Divya, additional, Bernard, Léa, additional, Shah, Nirali N., additional, Walter, Roland B., additional, Perales, Miguel-Angel, additional, Mapara, Markus Y., additional, Tamari, Roni, additional, Loken, Michael, additional, Breitschwerdt, Kyle, additional, Nath, Sritama, additional, Raffel, Glen D, additional, and Koehne, Guenther, additional

Published
2024
Full Text
View/download PDF

16. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author

O'Connor, Timothy E, primary, Lin, Chenyu, additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Faramand, Rawan G, additional, Kopmar, Noam E., additional, Dykes, Kaitlyn C, additional, Jeyakumar, Nikeshan, additional, Dekker, Simone E., additional, Gupta, Vishal, additional, Ahmed, Mohamed, additional, Logan, Aaron C., additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Tracy, Sean, additional, Kubiak, Michal, additional, Mukherjee, Akash, additional, Majhail, Navneet S., additional, Battiwalla, Minoo, additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Shaughnessy, Paul J., additional, Ladha, Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Solh, Melhem M, additional, Lee, Catherine J., additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Tsai, Dr. Stephanie B., additional, and Dholaria, Dr. Bhagirathbhai, additional

Published
2024
Full Text
View/download PDF

17. P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS

Author

Koehne, Guenther, primary, Tomlinson, Benjamin, additional, Suh, Hyung, additional, Koura, Divya, additional, Cho, Christina, additional, Bambace, Nadia M, additional, Bernard, Léa, additional, Shah, Nirali N, additional, Walter, Roland, additional, Dipersio, John, additional, Perales, Miguel-Angel, additional, Loken, Michael R, additional, Breitschwerdt, Kyle, additional, Nath, Sritama, additional, Raffel, Glen, additional, and Cooper, Brenda W, additional

Published
2023
Full Text
View/download PDF

18. Vaccine response after pneumococcal vaccination in allogeneic hematopoietic stem cell transplant recipients.

Author

Cheplowitz, Halle, Patel, Nimish, Kim, Alexander, Logan, Cathy, Law, Nancy, Koura, Divya, Haste, Nina, Medley, Katherine, Trinh, Julie, Sanders, Tyler, Taremi, Mahnaz, and Saunders, Ila M

Subjects
STREPTOCOCCAL disease prevention, SCIENTIFIC observation, PATIENTS, PNEUMOCOCCAL vaccines, RETROSPECTIVE studies, ACQUISITION of data, VACCINE effectiveness, SEROTYPES, MEDICAL records, HEMATOPOIETIC stem cell transplantation, TRANSPLANTATION of organs, tissues, etc., EVALUATION
Abstract

Current guidelines for vaccination in allogeneic hematopoietic stem cell transplant (HCT) recipients recommend initiation of pneumococcal vaccination series three to six months post-HCT, with most data supporting initiation at six months due to a more robust immune response. This single-center, retrospective, observational chart review aimed to evaluate the impact of initiating the pneumococcal vaccine series at three months post-HCT compared to six months post-HCT. The primary endpoints were defined as a percentage of patients with a serologic response of >1 and >1.3 µg/mL for over 50% of the defined serotypes. Outcomes showed no difference in immunologic response between the two groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. First use of ibrutinib for the treatment of post‐transplant central nervous system graft‐versus‐host disease.

Author

Trando, Aaron, Dunn‐Pirio, Anastasie, Koura, Divya, and Goodman, Aaron M.

Subjects
CENTRAL nervous system diseases, MYELIN sheath diseases, GRAFT versus host disease, DIFFUSE large B-cell lymphomas, NEUROLOGICAL disorders, BRUTON tyrosine kinase, THERAPEUTICS
Abstract

Chronic graft-versus-host disease (cGVHD) represents a serious complication of allogeneic haematopoietic stem cell transplant that occurs in 20%-80% of patients. A leading hypothesis posits that chronic CNS-GHVD onset stems from sequential CNS infiltration of donor CD8 SP + sp T cells, donor CD4 SP + sp T cells and donor bone marrow-derived macrophages (BMDMs). 4 Polchlopek Blasiak K, Simonetta F, Vargas MI, Chalandon Y. Central nervous system graft-versus-host disease (CNS-GvHD) after allogeneic haematopoietic stem cell transplantation. [Extracted from the article]

Published
2023
Full Text
View/download PDF

22. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire

Author

Suessmuth, Yvonne, Mukherjee, Rithun, Watkins, Benjamin, Koura, Divya T., Finstermeier, Knut, Desmarais, Cindy, Stempora, Linda, Horan, John T., Langston, Amelia, Qayed, Muna, Khoury, Hanna J., Grizzle, Audrey, Cheeseman, Jennifer A., Conger, Jason A., Robertson, Jennifer, Garrett, Aneesah, Kirk, Allan D., Waller, Edmund K., Blazar, Bruce R., Mehta, Aneesh K., Robins, Harlan S., and Kean, Leslie S.

Published
2015
Full Text
View/download PDF

23. Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Author

Cooper, Brenda W., primary, Suh, Hyung C., additional, Koura, Divya, additional, Koehne, Guenther, additional, Cho, Christina, additional, Bambace, Nadia M., additional, Bernard, Léa, additional, Shah, Nirali N., additional, Walter, Roland B., additional, DiPersio, John F., additional, Nath, Sritama, additional, Lee-Sundlov, Melissa M., additional, Lacy, Ali, additional, Stanizzi, Darren, additional, Kuhn, Karen, additional, Whangbo, Jennifer S., additional, Slapak, Christopher, additional, and Raffel, Glen D., additional

Published
2022
Full Text
View/download PDF

24. In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial

Author

Koura, Divya T., Horan, John T., Langston, Amelia A., Qayed, Muna, Mehta, Aneesh, Khoury, Hanna J., Harvey, R. Donald, Suessmuth, Yvonne, Couture, Cynthia, Carr, Jennifer, Grizzle, Audrey, Johnson, Heather R., Cheeseman, Jennifer A., Conger, Jason A., Robertson, Jennifer, Stempora, Linda, Johnson, Brandi E., Garrett, Aneesah, Kirk, Allan D., Larsen, Christian P., Waller, Edmund K., and Kean, Leslie S.

Published
2013
Full Text
View/download PDF

25. A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care

Author

Koura, Divya, primary, Tzachanis, Dimitrios, additional, Ball, Edward D., additional, Costello, Caitlin, additional, Goodman, Aaron M, additional, Mangan, James K., additional, Mulroney, Carolyn, additional, Maroge, Joseph, additional, Padilla, Michelle, additional, Breslin, Peggy, additional, Garrett, Jodi, additional, and McConnell, Kimberly, additional

Published
2021
Full Text
View/download PDF

27. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, Tsai, Stephanie B., Roloff, Gregory W, Zhang, Amy, Aldoss, Ibrahim, Kopmar, Noam E., Dekker, Simone E., Jeyakumar, Nikeshan, Gupta, Vishal K, O'Connor, Timothy E, Dykes, Kaitlyn C, Ahmed, Mohamed, Dholaria, Bhagirathbhai, Zambrano, Hector, Bradshaw, Danielle, Logan, Aaron C., Tracy, Sean, Kubiak, Michal, Solh, Melhem M., Mercadal, Santiago, Schwartz, Marc, Mukherjee, Akash, Battiwalla, Minoo, Shaughnessy, Paul, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Ladha, Abdullah, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Sasine, Joshua, Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Pullarkat, Vinod, Cassaday, Ryan D, Miller, Katharine, Muffly, Lori S., Galal, Ahmed, Shah, Bijal D., and Faramand, Rawan

Published
2023
Full Text
View/download PDF

28. Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)

Author

Gupta, Vishal K, Roloff, Gregory W, Muffly, Lori S., Aldoss, Ibrahim, Kopmar, Noam E., Lin, Chenyu, Dekker, Simone E., Jeyakumar, Nikeshan, O'Connor, Timothy E, Zhang, Amy, Miller, Katharine, Dykes, Kaitlyn C, Ahmed, Mohamed, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shabaz, Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Yaghmour, George, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Tsai, Stephanie B., Sasine, Joshua, Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Stock, Wendy, Galal, Ahmed, Pullarkat, Vinod, Cassaday, Ryan D, Shah, Bijal D., Faramand, Rawan, and Oliai, Caspian H.

Published
2023
Full Text
View/download PDF

29. The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Aldoss, Ibrahim, Roloff, Gregory W, Advani, Anjali S., Kopmar, Noam E., Lin, Chenyu, Dekker, Simone E., Gupta, Vishal K, Jeyakumar, Nikeshan, O'Connor, Timothy E, Zhang, Amy, Miller, Katharine, Dykes, Kaitlyn C, Ahmed, Mohamed, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Yaghmour, George, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Galal, Ahmed, Pullarkat, Vinod, Cassaday, Ryan D, Shah, Bijal D., Faramand, Rawan, and Muffly, Lori S.

Published
2023
Full Text
View/download PDF

30. Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Author

Shah, Nirali N., Azzi, Jacques, Cooper, Brenda W, Deol, Abhinav, DiPersio, John, Koura, Divya, McClune, Brian, Muffly, Lori S., Mushtaq, Muhammad Umair, Narayan, Rupa, Suh, Hyung Chan, Yanik, Gregory, Nath, Sritama, Whangbo, Jennifer, and Koehne, Guenther

Published
2023
Full Text
View/download PDF

31. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author

O'Connor, Timothy E, Lin, Chenyu, Roloff, Gregory W, Zhang, Amy, Aldoss, Ibrahim, Faramand, Rawan, Kopmar, Noam E., Dykes, Kaitlyn C, Jeyakumar, Nikeshan, Dekker, Simone E., Gupta, Vishal K, Ahmed, Mohamed, Logan, Aaron C., Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shabaz, Mathews, John, Shaughnessy, Paul, Ladha, Abdullah, Yaghmour, George, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Cassaday, Ryan D, Shah, Bijal D., Miller, Katharine, Muffly, Lori S., Galal, Ahmed, Tsai, Stephanie B., and Dholaria, Bhagirathbhai

Published
2023
Full Text
View/download PDF

32. Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

Author

Kopmar, Noam E., Gooley, Ted, Roloff, Gregory W, Aldoss, Ibrahim, Lin, Chenyu, Dekker, Simone E., Gupta, Vishal K, Jeyakumar, Nikeshan, O'connor, Timothy, Dykes, Kaitlyn C, Ahmed, Mohamed, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shabaz, Shaughnessy, Paul, Mathews, John, Logan, Aaron C., Ladha, Abdullah, Yaghmour, George, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Galal, Ahmed, Pullarkat, Vinod, Shah, Bijal D., Faramand, Rawan, Muffly, Lori S., and Cassaday, Ryan D

Published
2023
Full Text
View/download PDF

33. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

Author

DiPersio, John, Cooper, Brenda W, Suh, Hyung C, Koura, Divya, Bernard, Lea, Shah, Nirali N., Walter, Roland B., Perales, Miguel-Angel, Mapara, Markus, Tamari, Roni, Loken, Michael R., Breitschwerdt, Kyle, Nath, Sritama, Raffel, Glen D, and Koehne, Guenther

Published
2023
Full Text
View/download PDF

34. Survivorship, Version 2.2020: Featured Updates to the NCCN Guidelines

Author

Denlinger, Crystal S., Sanft, Tara, Moslehi, Javid J., Overholser, Linda, Armenian, Saro, Baker, K. Scott, Broderick, Gregory, Demark-Wahnefried, Wendy, Friedman, Debra L., Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L., Melisko, Michelle, Mooney, Kathi, Moore, Halle C. F., Moryl, Natalie, O’Connor, Tracey, Paskett, Electra D., Patel, Chirayu, Peterson, Lindsay, Pirl, William, Rodriguez, M. Alma, Ruddy, Kathryn J., Shockney, Lillie, Smith, Sophia, Syrjala, Karen L., Tevaarwerk, Amye, Zee, Phyllis, McMillian, Nicole R., and Freedman-Cass, Deborah A.

Subjects
Adult, Neoplasms, Practice Guidelines as Topic, Humans, Mass Screening, Immunization, Survivors, Survivorship, Exercise, humanities, Article, Body Weight Maintenance
Abstract

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment, with the goal of helping healthcare professionals who work with survivors, including those in primary care. The guidelines also provide recommendations to help clinicians promote physical activity, weight management, and proper immunizations in survivors and facilitate care coordination to ensure that all of the survivors' needs are addressed. These NCCN Guidelines Insights summarize additions and changes made to the guidelines in 2020 regarding cardiovascular disease risk assessment and screening for subsequent primary malignancies.

Published
2020

36. Survivorship, Version 2.2019: Featured Updates to the NCCN Guidelines

Author

Sanft, Tara, Denlinger, Crystal S., Armenian, Saro, Baker, K. Scott, Broderick, Gregory, Demark-Wahnefried, Wendy, Friedman, Debra L., Goldman, Mindy, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, Lally, Robin M., Langbaum, Terry S., McDonough, Allison L., Melisko, Michelle, Mooney, Kathi, Moore, Halle C.F., Moslehi, Javid J., O’Connor, Tracey, Overholser, Linda, Paskett, Electra D., Peterson, Lindsay, Pirl, William, Rodriguez, M. Alma, Ruddy, Kathryn J., Smith, Sophia, Syrjala, Karen L., Tevaarwerk, Amye, Urba, Susan G., Zee, Phyllis, McMillian, Nicole R., and Freedman-Cass, Deborah A.

Subjects
Neoplasms, Humans, Guidelines as Topic, Survivorship, Exercise, humanities, Article, Body Weight Maintenance
Abstract

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of cancer and cancer treatment to aid healthcare professionals who work with survivors of adult-onset cancer. Guidance is also provided to help promote physical activity, weight management, and proper immunizations in survivors and to facilitate care coordination to ensure that all needs are addressed. These NCCN Insights summarize some of the topics discussed by the NCCN Survivorship Panel during the 2019 update of the guidelines, including the survivorship population addressed, ways to improve care coordination, and pain management.

Published
2019

38. A Case of Aplastic Anemia Associated With Long-Term Metronidazole Use.

Author

Sam, Andrew M., Saunders, Ila M., Taplitz, Randy, and Koura, Divya

Subjects
APLASTIC anemia, BLOOD diseases, METRONIDAZOLE, TREATMENT duration
Abstract

Metronidazole is a nitroimidazole antibacterial agent that is highly effective for the treatment of protozoal and anaerobic infections. Metronidazole is known to cause hematologic adverse effects, including a reversible mild neutropenia; in rare circumstances, thrombocytopenia has been associated with metronidazole treatment. We present a case of aplastic anemia related to the extended use of metronidazole. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

39. Exhaustive TCR Deep Sequencing Reveals That CMV Reactivation Fundamentally Resets Immune Reconstitution after Transplant and Results in Significant Deficits in the Effector Memory TCR Repertoire

Author

Suessmuth, Yvonne, primary, Koura, Divya, additional, Finstermeier, Knut, additional, Desmarais, Cindy, additional, Horan, John, additional, Langston, Amelia, additional, Qayed, Muna, additional, Khoury, H. Jean, additional, Watkins, Benjamin K., additional, Robins, Harlan, additional, Mukherjee, Rithun, additional, Blazar, Bruce R., additional, Waller, Edmund K., additional, Mehta, Aneesh, additional, and Kean, Leslie S., additional

Published
2015
Full Text
View/download PDF

41. A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis.

Author

Dykes K, Tzachanis D, and Koura D

Subjects
Humans, Abatacept therapeutic use, Male, Middle Aged, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Adult, Female, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Graft vs Host Disease prevention & control, Calcineurin Inhibitors therapeutic use, Calcineurin Inhibitors adverse effects
Abstract

Post-allogeneic hematopoietic cell transplant (HCT) immunosuppression regimens are given as graft-versus-host disease (GVHD) prophylaxis. Most GVHD prophylaxis regimens are based on calcineurin inhibitors (CNIs). Unfortunately, CNIs are associated with significant associated morbidity, frequently cannot be tolerated, and often need to be discontinued. There is no consensus as to which alternative immunosuppression should be used in cases where CNIs have to be permanently discontinued. Cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA4-Ig) blocking agents are well tolerated and have been used extensively in patients with autoimmune disease and as post-transplant immunosuppression. There are two CTLA4-Ig agents: belatacept and abatacept. Belatacept is routinely used in adult kidney transplantation to prevent rejection and abatacept has been approved by the Food and Drug Administration (FDA) for GVHD prophylaxis in patients undergoing a matched or one allele-mismatched unrelated allogenic HCT. Herein, we describe a case in which abatacept was given off-label to replace tacrolimus GVHD prophylaxis in a patient with neurotoxicity undergoing haploidentical HCT. This case suggests that CTLA4-Ig blockade may be a good alternative to a CNI in cases where the CNI needs to be discontinued and warrants further investigation., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dimitrios Tzachanis has received research funding from Bristol Myers Squibb and Divya Koura has served on the advisory board for Bristol Myers Squibb within the past 12 months.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results